Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilofexor (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIMIS
  • Sponsors Gilead Sciences

Most Recent Events

  • 22 Oct 2024 According to a Gilead Sciences media release, data from this study will be presented at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif.
  • 24 Jun 2023 Results assessing cilofexor efficacy (in termsof fibrosis progression) and safety in patients with non-cirrhotic primary sclerosing cholangitis, presented at the European Association for the Study of the Liver Congress 2023.
  • 14 Jun 2023 According to a Gilead Sciences media release, data from this study to be presented at the European Association for the Study of the Liver (EASL) Congress 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top